Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2012 | 03:17pm CET
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21 MERCK : StayWell and VUCA Health Collaborate to Expand Availability of Medicatio..
02/21 BRISTOL-MYERS SQUIBB CO (NYSE : BMY), Merck & Co., Inc. (NYSE:MRK), And Other Ph..
02/20 MERCK : StayWell and VUCA Health Collaborate to Expand Availability of Medicatio..
02/16 MERCK : Studies from Merck & Company Provide New Data on Laboratory Animal Resea..
02/16 MERCK : Studies from Merck & Company Update Current Data on Science (Development..
02/16 MERCK : Studies from Merck & Company Update Current Data on Tuberculosis (Thiazo..
02/16 MERCK : New Findings from Merck & Company Describe Advances in Analytical Scienc..
02/16 MERCK : Data on Science Reported by Researchers at Merck & Company (Structural c..
02/16 MERCK : Investigators at Merck & Company Describe Findings in Alimentary Pharmac..
More news
Sector news : Pharmaceuticals - NEC
12:03pDJBAYER : CEO Confident Monsanto Purchase Will Be Approved by End of Year -- Updat..
10:03aDJBAYER : Upbeat Bayer Posts Lower Profit With Monsanto in its Sights--Update
08:48aDJBRISTOL MYERS SQUIBB : New Pressure on Drug Giant -- WSJ
08:48aDJWHAT'S NEWS : Business & Finance -- WSJ
08:02aDJBAYER : Fourth-Quarter Net Profit Falls 26%
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/21 Merck Provides Keytruda For Bionomics Phase 1 Trial On Combination With BNC10..
02/21 ALLERGAN REPORTS Q4 : Multiple Analyses
02/21 BIOTECH FORUM DAILY DIGEST : Biotech Continues To Gain Momentum. Alzheimer's Res..
02/17 INCYTE : Many Strengths, Small EPS, So What's It Worth?
Advertisement
Financials ($)
Sales 2017 39 728 M
EBIT 2017 13 523 M
Net income 2017 8 459 M
Debt 2017 3 738 M
Yield 2017 2,87%
P/E ratio 2017 19,13
P/E ratio 2018 15,96
EV / Sales 2017 4,64x
EV / Sales 2018 4,50x
Capitalization 180 537 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,5 $
Spread / Average Target 4,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.11.23%180 537
JOHNSON & JOHNSON3.86%325 539
ROCHE HOLDING LTD.4.90%212 000
PFIZER INC.3.51%204 018
NOVARTIS AG3.51%202 892
SANOFI4.72%109 519
More Results